CIMAS Health Group chief executive officer Vulindlela Lester Ndlovu says the success of government’s National Development Strategy 1 (NDS1) blueprint falls squarely on the private sector working together with the government.
Ndlovu made the remarks on Wednesday while addressing guests at the International Business Conference 2024 which is part of the weeklong Zimbabwe International Trade in Bulawayo.
For the second year running Cimas Health Group is the platinum sponsor for the ZITF International Business Conference.
“Our wish list for our industry, consistent with this year’s ZITF great theme, firstly, I must say that the government of Zimbabwe initiated bold strategies that are disrupting the status quo through the NDS1 blueprint. However, the success of this blueprint falls squarely on the private sector working together with the government,” said Ndlovu
“We find the pharmaceutical value chain strategies most exciting. As Cimas Health Group we intent to maximise on the whole healthcare value chain. However, zeroing in on the pharmaceutical value chain, we have seen an increase in locally manufactured medical consumables and pharmaceuticals. We are, however, cognisant that as a country we are still lagging in meeting the NDS1 expectations.”
Ndlovu called for the mobilisation of more funding to capacitate local manufacturers, while also advocated for a Health Investment Fund, “whose success will be underpinned by sustainable support given to the manufacturers by us the private sector and the public sector”.
Keep Reading
- Building narratives: Chindiya empowers girls through sports
- Building narratives: Chindiya empowers girls through sports
- Nama successfully hosts second golf day
- Nama successfully hosts second golf day
Ndlovu said this year’s ZITF theme Innovation: The Catalyst to Industrialisation and Trade quite was so inspiring that it should galvanise private healthcare player to contribute to innovations that can take the country forward.
“I am excited to advise that this year, as Cimas Health Group, we are launching a genomic sequencing service. This will enable us to identify individuals who could potentially be at risk of cancer and other chronic diseases. Our sequencer will also be able to do wellness and pharmacogenetic testing. In the end it will help in the development of precision medicine,” he added.